Physician profile

Colin Lee

Optometrist · Menomonee Falls, WI

NPI 1720646193

$774.66

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$321.23

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Alcon Vision LLC $425.72 2019-2024 Total30, Dailies Total1
Bausch & Lomb, A Division of Bausch Health US, LLC $121.54 2021
Coopervision INC. $107.32 2023 Biofinity Contact Lens
Bausch & Lomb Americas INC. $57.31 2022-2023 Lotemax Sm, Vyzulta
Novartis Pharmaceuticals Corporation $25.43 2022
Kala Pharmaceuticals, INC. $14.12 2022
Visioneering Technologies, INC. $12.22 2021
Johnson & Johnson Vision Care, INC. $11.00 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Colin Lee

$774.66

in general payments reported 2019-2025

Years
2019-2024
Top company
Alcon Vision LLC

https://glasscript.com/doctor/5936109/colin-lee

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.